Sponsor study identifier
Secondary identifiers
NIH
NIH
observational
817
1 country
1
Study Start
November 20, 2021
Actual (reported)Primary Completion
March 20, 2025
Actual (reported)Study Completion
March 20, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 20, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 21, 2021
Actual (reported)November 16, 2021
Actual (reported)November 20, 2021
Actual (reported)March 20, 2025
Actual (reported)March 20, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Patient's Experiences with Office-Based Opioid Treatment
This is an eight-item scale that measures the degree to which participants report being able to access buprenorphine treatment-related appointments and medications before and during the COVID-19 pandemic. Participants will be asked to rate each of the eight questions on a 7-point Likert scale from 1 = "extremely easy" to 7= "extremely difficult."
Day 1
Reasons for Abstaining from Opioids Questionnaire
This 17-item scale will measure participant ratings of the importance of 17 factors that motivate abstinence from illicit drug use during office-based opioid treatment. Participants will be asked to rate each of these 17 items on a scale from 0 = "not at all important" to 4 = "extremely important."
Day 1
Patients' Attitudes Toward the Use of Cannabis During Office-Based Opioid Treatment
Survey investigating patients' experiences with buprenorphine treatment for Opioid Use Disorder before and during the COVID-19 pandemic
Survey investigating the factors that motivate patients to abstain from opioid drug use during buprenorphine treatment for Opioid Use Disorder
Survey investigating patients' attitudes towards and experiences with cannabis use during buprenorphine treatment for Opioid Use Disorder.
Survey investigating patients' attitudes towards and experiences with cigarettes and e-cigarettes use during buprenorphine treatment for Opioid Use Disorder.
Survey investigating patients' attitudes towards and experiences with benzodiazepine use during buprenorphine treatment for Opioid Use Disorder.
The subject population consists of adults aged 18+ who live in Massachusetts and are currently prescribed buprenorphine by a healthcare provider to treat OUD. Those under the age of 18 will be screened out of the investigation during the consent process. In addition, because many of the survey questions used in this investigation are based on established survey instruments that were created in the English language and validated among English-speaking participants, we will limit the subject population or this study to English-speaking adults.
CHA Center for Mindfulness and Compassion
Cambridge, Massachusetts, 02141, United States
Zev Schuman-Olivier, MD
Cambridge Health Alliance
Joseph Rosansky
Cambridge Health Alliance
817 participants (actual enrollment reported by the registry).
First Submitted
October 21, 2021
First Posted
November 16, 2021
Study Start
November 20, 2021
Actual (reported)Measuring Acute Drug Demand in Humans
Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which they feel cannabis use is acceptable during office-based opioid treatment (OBOT), they believe that their prescribers' feel cannabis use is acceptable during OBOT, and they feel comfortable discussing cannabis use with their buprenorphine prescribers.
Day 1
Patients' Attitudes Toward the Use of Cigarettes/E-Cigarettes During Office-Based Opioid Treatment
Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which patients should be encouraged to quit smoking cigarettes and e-cigarette during office-based opioid treatment (OBOT) and the degree to which they feel smoking helps manage cravings during OBOT.
Day 1
Patients' Attitudes Toward and Experiences with the Use of Benzodiazepines during Office-Based Opioid Treatment
Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which benzodiazepine use is acceptable during office-based opioid treatment (OBOT), they feel OBOT providers find benzodiazepine use by their patients acceptable, and they feel comfortable openly discussing their benzodiazepine use with their buprenorphine prescriber.
Day 1
Contact the study team to confirm eligibility.
Primary Completion
March 20, 2025
Actual (reported)Study Completion
March 20, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 11, 2025
Record last verified: 2025-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: